Catalyzing transcriptomics research in cardiovascular disease: The CardioRNA COST action CA17129

Clarissa Pedrosa da Costa Gomes; Bence Ágg; Andrejaana Andova; Serdal Arslan; Andrew Baker; Monika Barteková; Dimitris Beis; Fay Betsou; Stephanie Bezzina Wettinger; Branko Bugarski; Gianluigi Condorelli; Gustavo José Justo da Silva; Sabrina Danilin; David de Gonzalo-Calvo; Alfonso Buil; Maria Carmo-Fonseca; Francisco J. Enguita; Kyriacos Felekkis; Peter Ferdinandy; Mariann Gyöngyösi; Matthias Hackl; Kanita Karaduzovic-Hadziabdic; Jan Hellemans; Stephane Heymans; Markéta Hlavackova; Morten Andre Hoydal; Aleksandra Jankovic; Amela Jusic; Dimitris Kardassis; Risto Kerkelä; Gabriela M. Kuster; Päivi Lakkisto; Przemyslaw Leszek; Mitja Lustrek; Lars Maegdefessel; Fabio Martelli; Susana Novella; Timothy O'Brien; Christos Papaneophytou; Thierry Pedrazzini; Florence Pinet; Octavian Popescu; Ines Potočnjak; Emma Robinson; Shlomo Sasson; Markus Scholz; Maya Simionescu; Monika Stoll; Zoltan V. Varga; Yvan Devaux; EU-CardioRNA COST Action (CA17129)

doi:10.3390/NCRNA5020031

Catalyzing transcriptomics research in cardiovascular disease: The CardioRNA COST action CA17129

Clarissa Pedrosa da Costa Gomes, Bence Ágg, Andrejaana Andova, Serdal Arslan, Andrew Baker, Monika Barteková, Dimitris Beis, Fay Betsou, Stephanie Bezzina Wettinger, Branko Bugarski, Gianluigi Condorelli, Gustavo José Justo da Silva, Sabrina Danilin, David de Gonzalo-Calvo, Alfonso Buil, Maria Carmo-Fonseca, Francisco J. Enguita, Kyriacos Felekkis, Peter Ferdinandy, Mariann GyöngyösiMatthias Hackl, Kanita Karaduzovic-Hadziabdic, Jan Hellemans, Stephane Heymans, Markéta Hlavackova, Morten Andre Hoydal, Aleksandra Jankovic, Amela Jusic, Dimitris Kardassis, Risto Kerkelä, Gabriela M. Kuster, Päivi Lakkisto, Przemyslaw Leszek, Mitja Lustrek, Lars Maegdefessel, Fabio Martelli, Susana Novella, Timothy O'Brien, Christos Papaneophytou, Thierry Pedrazzini, Florence Pinet, Octavian Popescu, Ines Potočnjak, Emma Robinson, Shlomo Sasson, Markus Scholz, Maya Simionescu, Monika Stoll, Zoltan V. Varga, Yvan Devaux^*, EU-CardioRNA COST Action (CA17129)

^*Corresponding author for this work

Cardiovascular Research Unit

Research output: Contribution to journal › Article › Research › peer-review

17 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field. COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).

Original language	English
Article number	31
Journal	Non-coding RNA
Volume	5
Issue number	2
DOIs	https://doi.org/10.3390/NCRNA5020031
Publication status	Published - 2019

Keywords

Best practices and guidelines
Cardiovascular disease
Personalized medicine
Transcriptomics
Translational research

Access to Document

10.3390/NCRNA5020031

Cite this

da Costa Gomes, C. P., Ágg, B., Andova, A., Arslan, S., Baker, A., Barteková, M., Beis, D., Betsou, F., Wettinger, S. B., Bugarski, B., Condorelli, G., da Silva, G. J. J., Danilin, S., de Gonzalo-Calvo, D., Buil, A., Carmo-Fonseca, M., Enguita, F. J., Felekkis, K., Ferdinandy, P., ... EU-CardioRNA COST Action (CA17129) (2019). Catalyzing transcriptomics research in cardiovascular disease: The CardioRNA COST action CA17129. Non-coding RNA, 5(2), Article 31. https://doi.org/10.3390/NCRNA5020031

@article{9541943552fd40b8b90baa8ba113805c,

title = "Catalyzing transcriptomics research in cardiovascular disease: The CardioRNA COST action CA17129",

abstract = "Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field. COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).",

keywords = "Best practices and guidelines, Cardiovascular disease, Personalized medicine, Transcriptomics, Translational research",

author = "{da Costa Gomes}, {Clarissa Pedrosa} and Bence {\'A}gg and Andrejaana Andova and Serdal Arslan and Andrew Baker and Monika Bartekov{\'a} and Dimitris Beis and Fay Betsou and Wettinger, {Stephanie Bezzina} and Branko Bugarski and Gianluigi Condorelli and {da Silva}, {Gustavo Jos{\'e} Justo} and Sabrina Danilin and {de Gonzalo-Calvo}, David and Alfonso Buil and Maria Carmo-Fonseca and Enguita, {Francisco J.} and Kyriacos Felekkis and Peter Ferdinandy and Mariann Gy{\"o}ngy{\"o}si and Matthias Hackl and Kanita Karaduzovic-Hadziabdic and Jan Hellemans and Stephane Heymans and Mark{\'e}ta Hlavackova and Hoydal, {Morten Andre} and Aleksandra Jankovic and Amela Jusic and Dimitris Kardassis and Risto Kerkel{\"a} and Kuster, {Gabriela M.} and P{\"a}ivi Lakkisto and Przemyslaw Leszek and Mitja Lustrek and Lars Maegdefessel and Fabio Martelli and Susana Novella and Timothy O'Brien and Christos Papaneophytou and Thierry Pedrazzini and Florence Pinet and Octavian Popescu and Ines Poto{\v c}njak and Emma Robinson and Shlomo Sasson and Markus Scholz and Maya Simionescu and Monika Stoll and Varga, {Zoltan V.} and Yvan Devaux and {EU-CardioRNA COST Action (CA17129)}",

note = "Funding Information: Funding: This work is supported by COST (European Cooperation in Science and Technology) Action EU-CardioRNA CA17129. YD is the chair and CE is the vice-chair of the European COST Action CA17129, CardioRNA. Funding Information: This work is supported by COST (European Cooperation in Science and Technology) Action EU-CardioRNA CA17129. YD is the chair and CE is the vice-chair of the European COST Action CA17129, CardioRNA Publisher Copyright: {\textcopyright} 2018 by the authors.",

year = "2019",

doi = "10.3390/NCRNA5020031",

language = "English",

volume = "5",

journal = "Non-coding RNA",

issn = "2311-553X",

publisher = "MDPI AG",

number = "2",

}

da Costa Gomes, CP, Ágg, B, Andova, A, Arslan, S, Baker, A, Barteková, M, Beis, D, Betsou, F, Wettinger, SB, Bugarski, B, Condorelli, G, da Silva, GJJ, Danilin, S, de Gonzalo-Calvo, D, Buil, A, Carmo-Fonseca, M, Enguita, FJ, Felekkis, K, Ferdinandy, P, Gyöngyösi, M, Hackl, M, Karaduzovic-Hadziabdic, K, Hellemans, J, Heymans, S, Hlavackova, M, Hoydal, MA, Jankovic, A, Jusic, A, Kardassis, D, Kerkelä, R, Kuster, GM, Lakkisto, P, Leszek, P, Lustrek, M, Maegdefessel, L, Martelli, F, Novella, S, O'Brien, T, Papaneophytou, C, Pedrazzini, T, Pinet, F, Popescu, O, Potočnjak, I, Robinson, E, Sasson, S, Scholz, M, Simionescu, M, Stoll, M, Varga, ZV, Devaux, Y & EU-CardioRNA COST Action (CA17129) 2019, 'Catalyzing transcriptomics research in cardiovascular disease: The CardioRNA COST action CA17129', Non-coding RNA, vol. 5, no. 2, 31. https://doi.org/10.3390/NCRNA5020031

TY - JOUR

T1 - Catalyzing transcriptomics research in cardiovascular disease

T2 - The CardioRNA COST action CA17129

AU - da Costa Gomes, Clarissa Pedrosa

AU - Ágg, Bence

AU - Andova, Andrejaana

AU - Arslan, Serdal

AU - Baker, Andrew

AU - Barteková, Monika

AU - Beis, Dimitris

AU - Betsou, Fay

AU - Wettinger, Stephanie Bezzina

AU - Bugarski, Branko

AU - Condorelli, Gianluigi

AU - da Silva, Gustavo José Justo

AU - Danilin, Sabrina

AU - de Gonzalo-Calvo, David

AU - Buil, Alfonso

AU - Carmo-Fonseca, Maria

AU - Enguita, Francisco J.

AU - Felekkis, Kyriacos

AU - Ferdinandy, Peter

AU - Gyöngyösi, Mariann

AU - Hackl, Matthias

AU - Karaduzovic-Hadziabdic, Kanita

AU - Hellemans, Jan

AU - Heymans, Stephane

AU - Hlavackova, Markéta

AU - Hoydal, Morten Andre

AU - Jankovic, Aleksandra

AU - Jusic, Amela

AU - Kardassis, Dimitris

AU - Kerkelä, Risto

AU - Kuster, Gabriela M.

AU - Lakkisto, Päivi

AU - Leszek, Przemyslaw

AU - Lustrek, Mitja

AU - Maegdefessel, Lars

AU - Martelli, Fabio

AU - Novella, Susana

AU - O'Brien, Timothy

AU - Papaneophytou, Christos

AU - Pedrazzini, Thierry

AU - Pinet, Florence

AU - Popescu, Octavian

AU - Potočnjak, Ines

AU - Robinson, Emma

AU - Sasson, Shlomo

AU - Scholz, Markus

AU - Simionescu, Maya

AU - Stoll, Monika

AU - Varga, Zoltan V.

AU - Devaux, Yvan

AU - EU-CardioRNA COST Action (CA17129)

N1 - Funding Information: Funding: This work is supported by COST (European Cooperation in Science and Technology) Action EU-CardioRNA CA17129. YD is the chair and CE is the vice-chair of the European COST Action CA17129, CardioRNA. Funding Information: This work is supported by COST (European Cooperation in Science and Technology) Action EU-CardioRNA CA17129. YD is the chair and CE is the vice-chair of the European COST Action CA17129, CardioRNA Publisher Copyright: © 2018 by the authors.

PY - 2019

Y1 - 2019

N2 - Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field. COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).

AB - Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field. COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).

KW - Best practices and guidelines

KW - Cardiovascular disease

KW - Personalized medicine

KW - Transcriptomics

KW - Translational research

UR - http://www.scopus.com/inward/record.url?scp=85069910260&partnerID=8YFLogxK

U2 - 10.3390/NCRNA5020031

DO - 10.3390/NCRNA5020031

M3 - Article

AN - SCOPUS:85069910260

SN - 2311-553X

VL - 5

JO - Non-coding RNA

JF - Non-coding RNA

IS - 2

M1 - 31

ER -

Catalyzing transcriptomics research in cardiovascular disease: The CardioRNA COST action CA17129

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this